LEUKEMIC STEM CELL FREQUENCY COMBINED WITH MRD IS AN IMPORTANT BIOMARKER TO PREDICT RELAPSE IN ACUTE MYELOID LEUKEMIA. RESULTS FROM A PROSPECTIVE H102 STUDY

W. Zeijlemaker, R. Meijer, A. Kelder, J. Carbaat-Ham, Y. Oussoren-brockhoff, S. Snel, D. Veldhuizen, W. Scholten, J. Maertens, D. Breems, T. Pabst, M. Manz, V. Van der Velden, J. Slomp, P. Valk, J. Cloos, B. Lowenberg, G. Ossenkoppele, G. J. Schuurhuis

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)7-8
JournalHaematologica
Volume102
Publication statusPublished - 26 Jun 2017

Cite this

Zeijlemaker, W., Meijer, R., Kelder, A., Carbaat-Ham, J., Oussoren-brockhoff, Y., Snel, S., Veldhuizen, D., Scholten, W., Maertens, J., Breems, D., Pabst, T., Manz, M., Van der Velden, V., Slomp, J., Valk, P., Cloos, J., Lowenberg, B., Ossenkoppele, G., & Schuurhuis, G. J. (2017). LEUKEMIC STEM CELL FREQUENCY COMBINED WITH MRD IS AN IMPORTANT BIOMARKER TO PREDICT RELAPSE IN ACUTE MYELOID LEUKEMIA. RESULTS FROM A PROSPECTIVE H102 STUDY. Haematologica, 102, 7-8.